^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR R776H

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1m
    Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family. (PubMed, Lung Cancer)
    Although rare, germline p.R776H EGFR lung cancer mutations are over-represented in light or never smoking female patients who often also possess an additional somatic EGFR mutation. Treatment with TKIs appears suitable but further research is needed into the appropriate screening regime for unaffected carriers or light/never smokers.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR R776H
    3ms
    Investigating Hereditary Risk In Thoracic Cancers (INHERIT) (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Dana-Farber Cancer Institute | Active, not recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • YAP1 (Yes associated protein 1)
    |
    EGFR mutation • EGFR T790M • MET mutation • EGFR R776H
    11ms
    Germline EGFR mutations in lung cancer (Review). (PubMed, Oncol Lett)
    Individuals with germline mutations may develop lung cancer upon exposure to environmental stimuli such as smoking, air pollution or radiological contamination, or due to the occurrence of another somatic mutation. The present study recommends regular physical examinations as well as population-wide germline mutation screening for early detection and diagnosis of lung cancer.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR R776H
    over1year
    Investigating Hereditary Risk In Thoracic Cancers (INHERIT) (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRCA2 (Breast cancer 2, early onset) • YAP1 (Yes associated protein 1)
    |
    EGFR mutation • EGFR T790M • MET mutation • EGFR R776H
    over1year
    INHERIT EGFR - Studying Germline EGFR Mutations (clinicaltrials.gov)
    P=N/A, N=121, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Mar 2022 --> Mar 2024
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR expression • EGFR R776H
    over1year
    Investigating Hereditary Risk In Thoracic Cancers (INHERIT) (clinicaltrials.gov)
    P=N/A, N=500, Not yet recruiting, Dana-Farber Cancer Institute
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRCA2 (Breast cancer 2, early onset) • YAP1 (Yes associated protein 1)
    |
    EGFR mutation • EGFR T790M • MET mutation • EGFR R776H
    over1year
    Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules. (PubMed, J Cancer Res Clin Oncol)
    Her father, paternal aunt, and elder uncle harbored either one or both two mutations and were found with multiple pulmonary ground-glass or sub-solid nodules. Her 7-year-old daughter also inherited the same two mutations.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR R776H
    almost2years
    Lung Adenocarcinoma Associated With Germline EGFR R776H Variant: A Case Report and Review of the Literature. (PubMed, JCO Precis Oncol)
    No abstract available
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR R776H
    almost2years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Trial primary completion date: Mar 2022 --> Oct 2022
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over2years
    Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study. (PubMed, Front Oncol)
    A total of 19 patients were confirmed to have received EGFR tyrosine kinase inhibitors (TKIs), but the response to EGFR-TKIs differed among patients with different EGFR mutations. Chinese patients with lung cancer harbored unique and dispersive EGFR germline mutations and showed unique clinical and genetic characteristics, with varied response patterns to EGFR-TKI treatment.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR K757R • EGFR R776H • EGFR V774M
    over2years
    Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation. (PubMed, Lung Cancer)
    Our study demonstrated the responsiveness of compound R776H-L861Q mutations to afatinib. We also revealed the transmission of EGFR R776H and suggested it may confer the high susceptibility to lung cancer.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR R776H
    |
    Gilotrif (afatinib)
    over2years
    INHERIT EGFR - Studying Germline EGFR Mutations (clinicaltrials.gov)
    P=N/A, N=121, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Apr 2021 --> Mar 2022
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR expression • EGFR R776H
    3years
    [VIRTUAL] Molecular characteristics of EGFR exon 20 uncommon R776H mutation and response to osimertinib in NSCLC patients. (ASCO 2021)
    Presence of EGFR R776H mutation was rare in NSCLC patients and our retrospective study provides clinical evidence that Osimertinib could be of benefit and may potentially be an effective treatment strategy to improve survival outcomes in patients with EGFR R776H.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR C797S • EGFR exon 20 mutation • EGFR G719A • EGFR R776H
    |
    Tagrisso (osimertinib)
    3years
    ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report. (PubMed, J Med Case Rep)
    "In this particular case, we show that ARID1A gene mutations with sporadic MSI due to somatic MLH1 gene promoter methylation and MLH1 gene mutation could change the prognosis and define the response to immunotherapy in a patient with lung adenocarcinoma. Comprehensive solid and liquid biopsy tests are useful to find out resistance mechanisms to immune checkpoint inhibitors. Our data encourages the development of new therapies against ARID1A mutations and epigenomic methylation when involved in MSI neoplasms."
    Journal • Clinical
    |
    EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • EGFR mutation • RET fusion • ARID1A mutation • CDKN2A mutation • MLH1 mutation • BRCA mutation • EGFR R776H • EGFR fusion
    |
    OncoDEEP
    over3years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over3years
    [VIRTUAL] A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma (IASLC-WCLC 2020)
    Based on these findings, the patient was administered with afatinib (a dose of 30 mg/d) combined with bevacizumab. Conclusion This is the first report of co-mutation of EGFR R776H/G724S in a patient with lung adenocarcinoma. Afatinib may be a beneficial therapeutic option for a subset of NSCLC with rare EGFR co-mutation.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR positive • EGFR G724S • EGFR R776H
    |
    Avastin (bevacizumab) • Gilotrif (afatinib)
    almost4years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)